Last updated: February 25, 2026
What is the Drug Associated with NDC 69097-0210?
NDC 69097-0210 corresponds to Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy approved by the U.S. Food and Drug Administration (FDA) in May 2019 for the treatment of spinal muscular atrophy (SMA) in children under two years of age. It delivers a functional copy of the defective SMN1 gene via an adeno-associated virus vector.
Market Size and Epidemiology
Patient Population
SMA is a rare neuromuscular disorder with an incidence of approximately 1 in 10,000 live births. The eligible patient population in the U.S. under age two is estimated at:
| Metric |
Value |
Source |
| U.S. Births per year |
~3.7 million |
CDC (2022) [1] |
| SMA incidence |
1 in 10,000 |
SMA Foundation [2] |
| Estimated SMA type 1 patients under age 2 |
370 |
Calculated from above |
Market Penetration
As of 2022, approximately 2,000 patients have been treated globally, representing significant unmet need. The market is dominated by Zolgensma, with limited competition due to the therapy’s unique modality as a gene therapy.
Commercialization and Pricing
Price Point
Zolgensma’s list price is $2.1 million per administration in the U.S., making it the most expensive single-use gene therapy approved.
Cost Structure and Reimbursement
- The price includes the one-time infusion of the therapy.
- Many payers negotiate discounts; commercial coverage is widespread but varies.
- The Institute for Clinical and Economic Review (ICER) estimates the value-based price at approximately $1.9 million.
Market Access Strategies
- Novartis, the manufacturer, offers a range of financial assistance programs.
- Pay-for-performance arrangements are common, linking reimbursement to patient outcomes.
Competitive Landscape and Future Outlook
Current Competitors
- Ongoing gene therapy developments: Biogen and others are investing in SMA gene therapies, but none have received approval as of 2023.
- Small molecule treatments: Spinraza (nusinersen) and Evrysdi (risdiplam) are standard-of-care but require ongoing dosing, contrasting with Zolgensma’s single administration.
Pipeline and Emerging Therapies
- Several pipeline candidates aim to improve upon Zolgensma’s delivery or reduce costs.
- Potential biosimilars are unlikely due to the complexity of gene therapy manufacturing.
Market Growth Projections
| Year |
Estimated Number of Treated Patients |
Source |
| 2023 |
1,800 |
Internal estimate based on market penetration data |
| 2025 |
3,000 |
Industry analyst projections |
| 2030 |
4,500 |
Projected growth with increased newborn screening programs |
Price Trajectory Analysis
- Current Price: $2.1 million per dose.
- Projected Trend: Slight decline expected due to increased competition, biosimilar development, and payer negotiations.
- Forecast: Average price may decline to $1.9 million by 2025, aligning with value-based estimations.
Key Factors Influencing Price and Market Dynamics
- Regulatory approvals: Expanded indications or age ranges could broaden the market.
- Manufacturing costs: Economies of scale and process improvements could reduce costs, allowing for price adjustments.
- Reimbursement policies: Payer strategies may shift towards outcome-based payments, impacting profitability.
- New entrants: Competition could significantly shift price dynamics, especially if biosimilars gain approval.
Summary
| Metric |
Value |
Source |
| Current price per dose |
$2.1 million |
Novartis (2022) [3] |
| Estimated total U.S. patient population |
370 |
Calculated |
| Projected treated patients (2025) |
3,000 |
Industry estimate |
| Price range 2025 |
$1.8-1.9 million |
ICER valuation & industry forecasts |
Key Takeaways
- Zolgensma commands a premium pricing structure due to its gene therapy modality and small patient population.
- The drug’s market is expected to expand as newborn screening increases identification.
- Price projections indicate a slight downward trend driven by competition and negotiations.
- The overall market remains highly limited by the rarity of SMA and high manufacturing costs.
- Future growth hinges on regulatory approvals, payer strategies, and pipeline developments.
FAQs
1. What is the main factor influencing Zolgensma’s high price?
The cost reflects the complexity of manufacturing a one-time gene therapy designed for a small, specific patient population.
2. How does Zolgensma compare price-wise to other SMA treatments?
Spinraza (risdiplam) and Evrysdi are administered repeatedly, costing approximately $750,000-$1 million annually, whereas Zolgensma’s single dose is priced at $2.1 million.
3. Will prices decrease as competition emerges?
Potentially, as biosimilar gene therapies or alternative treatments develop, pressure on pricing will increase.
4. What factors could expand the treatment market?
Expanding age indications, increased newborn screening, and improved reimbursement strategies.
5. What are the primary risks to Zolgensma’s market dominance?
Regulatory delays, biosimilar entry, or negative payer reimbursement policies could impact sales.
References
- Centers for Disease Control and Prevention. (2022). Birth data and demographics. CDC.gov.
- SMA Foundation. (2022). Incidence and prevalence of SMA. SMA.org.
- Novartis. (2022). Zolgensma pricing and reimbursement updates. Novartis.com.
